Gut bacteria boost: could a probiotic help standard cancer drugs work better?
NCT ID NCT05122546
First seen Jan 11, 2026 · Last updated Jun 20, 2026 · Updated 22 times
Summary
This early-phase trial is testing whether adding a probiotic called CBM588 to the usual combination of cabozantinib and nivolumab can improve gut bacteria and potentially help treat advanced kidney cancer. The study involves 31 patients with metastatic or unresectable kidney cancer. Researchers will measure changes in the gut microbiome and look for any signs of tumor shrinkage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CBM588 (a probiotic bacteria), cabozantinib (a targeted therapy), and nivolumab (an immunotherapy)
What this could lead to
If it works, this could show that adding a probiotic to standard therapy improves gut health and boosts the immune system's ability to fight kidney cancer.
What could go wrong
This is a very early, small phase 1 pilot study with only 31 participants. It is designed mainly to see if the probiotic changes gut bacteria, not yet to prove it helps cancer. The combination may cause side effects from the drugs or probiotic.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.